ABOUT US

NuvoBio is a bio-medical technology company dedicated to expediting the development of peptide therapeutics. Using our novel Darwin AI technology platform to design highly specific binding peptides, we are developing intellectual property and advancing research and development in the areas of new synthetic drugs, immunotherapies and other unique applications.

 Through our strategic partnerships and global exclusive licensing agreements with leading drug research institutes and companies, NuvoBio is currently funding research & development projects in key areas including:

  1. Implementing unique molecular interaction & analytics using supercomputing technologies to design peptide drugs that bind to target proteins for therapeutic purposes
  2. Immunostimulatory peptides, Anti-microbial peptides, Anti-fungal & Anti-viral peptides (e.g., anti-SARS-Cov-2)
  3. Beta-lactamase Inhibitors & Protein Phosphatase Inhibitors
  4. Other non-medical applications for peptides, including anti-fungal peptides for use in agriculture

MEET THE TEAM

Dr. Michael C.J Cowpland

Chief Executive Officer
Entrepreneur in hardware and software development.

Dr. Michael Cowpland is a world renowned leader and entrepreneur in hardware and software development. Mike began his career at Bell Northern Research in 1964, working on electronic telephone systems, before moving to MicroSystems International where he became manager of silicon chip design. In 1973, he founded MITEL with Terence Matthews and was the company’s CEO for 10 years. During this time, MITEL achieved a 100 per cent annual growth rate and sales of more than $300 million. Attracted to the explosive growth in the software market, and eager for a new challenge, Mike founded Corel Corporation in 1985. Over the next 15 years, he led Corel to become one of the world’s top software companies, with 50 million users of CorelDRAW and WordPerfect worldwide. Mike earned a Bachelor of Science degree (Engineering) at Imperial College in England, a Master’s degree and a Ph.D. in Electrical Engineering from Carleton University. He also holds many honorary degrees and is a member of the development advisory board of Imperial College.

Dr. Kyle K. Biggar

Chief Science Officer Bioinformatics, drug design, and peptide biochemistry and protein function.

Dr. Kyle Biggar received his B.Sc. in both Chemistry and Biology from St. Francois Xavier University in 2008. He then received his Ph.D. degree from Carleton University in 2013. At that time, he also received the Governor General’s Gold medal for his research in Genomics and Molecular Physiology. In 2013, Dr. Biggar then moved to the Schulich Medical and Dental school at Western University where he worked to develop proteomic methods in peptide therapeutic discovery for the treatment of triple-negative breast cancers. In 2016, Dr. Biggar joined the Institute of Biochemistry at Carleton University, where he was also awarded the 2016 John C. Polanyi prize in Physiology and Medicine for his work in peptide therapeutics. His research focuses on peptide biochemistry, bioinformatics, and the development and characterization of peptide therapeutics.

John Chapman

Chief Financial Officer Financial operations and leadership

Mr. Chapman is an experienced in all facets of financial operations and leadership. From 2003 to 2005 Mr. Chapman held the positions of Director of Finance and Program Management Office at Amdocs Canadian Managed Services. From 1988 to 2003 Mr. Chapman held various positions at Bell Canada and BCE companies in the areas of Finance, Human Resources and Engineering. He received a Bachelor of Technology (Mechanical Engineering) from Ryerson Polytechnical Institute in 1988 and a Masters in Business Administration from the University of Ottawa in 1999. Mr. Chapman is a member of, and holds professional designations, with the Association of Professional Engineers of Ontario and the Institute of Certified Management Consultants of Ontario.

Dr. Valentina Lukinovic

Director Business Development Cancer target identification, characterization and validation

Dr. Valentina Lukinovic received her B.Sc. in Biotechnology at the University of Zagreb in 2011. She then received her M.Sc. in Bioprocess Engineering in 2013 (University of Zagreb) and her Ph.D. in Experimental Chemistry (University of Manchester) in 2017. During her graduate studies, she worked on toward the development of innovative therapies for malaria. This work was conducted at several eminent research institutions, including Cancer Research UK facility in Manchester (England) and the Institute for Advanced Biosciences in Grenoble (France). Dr. Lukinovic then continued her research at Cancer Research UK Manchester Institute, where she worked on the validation experiments on a drug candidate for glioma treatment. In 2019, she moved to Ottawa Ontario, where she currently specializes in peptide biochemistry and translational cancer research.

Dr. James Green (eng)

Development Lead Machine Learning Machine learning, proteomics, prediction of protein interaction

Dr. James Green received his B.A.Sc. in Systems Design Engineering from the University of Waterloo in 1998. He then received his M.Sc.(Eng.) and Ph.D. degrees from Queen’s University in 2000 and 2005, respectively, for research in the areas of computational genomics and proteomics. In 2000-2001, Dr. Green worked at Molecular Mining Corporation, a bioinformatics start-up company in Kingston Ontario, where he helped to develop novel analysis methods for the interpretation of gene expression data. In 2005, Dr. Green joined the Department of Systems and Computer Engineering at Carleton University where he is now a Full Professor. His research focuses on machine learning challenges in biomedical informatics, particularly in the presence of class imbalance and the prediction of rare events.

François Charih, MASc (eng)

Research Scientist High performance computing, AI/ML applications

During his graduate studies, he worked closely with the Ottawa company, Shoebox Audiometry, to apply machine learning approaches to the diagnostic analysis of patient data. Francois’ current research is focused on the intersection of proteomics, peptide biochemistry, and applied machine learning. His work converges on the development of computational approaches to engineer and screen peptide binders for therapeutic applications using state-of-the-art machine learning techniques.

Dr. Nour Nissan

Research Scientist
Bioinformatics

Dr. Nour Nissan earned her Bachelor of Science in Biochemistry from Carleton University in 2019. She then fast-tracked from the Master’s Biology program in 2020, and embarked on her Ph.D. journey in collaboration with Agriculture Canada. Throughout her academic pursuits, Dr. Nissan delved into the identification of novel candidate genes associated with economically significant traits in soybean. Her research revealed key genes responsible for early flowering and maturity, as well as elucidated novel protein interaction partners linked to resistance-related genes in soybean. Presently, Dr. Nissan is specializing in peptide biochemistry and contributing to antifungal research.